Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
gastroenterologyadvisor8h
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
infectiousdiseaseadvisor.com8h
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within 1 Year
Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.
Immunic announces IMU-856 demonstrated dose-dependent increase
Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...
Hosted on MSN20h
Ascletis announces positive results in Phase Ib oral GLP-1RA trial
The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.